Montana Based Company Dermaxon Receives Multiple NIH Funding Awards

Friday, July 30 2021

Montana based drug discovery company Dermaxon has notably received multiple NIH funding awards in recent years. Dermaxon targets the brain-skin connection to discover and develop novel therapeutic strategies to treat life threatening diseases and disorders such as pain, pruritus, and genetic disorders of skin keratinization.

The awards they have received are:

  • 2018 Phase 1 STTR Grant funding from the National Institute of Neurological Disorders and Stroke to support preclinical efficacy studies for a novel drug treatment for pain for up to $1.5 million.
  • 2018 Phase II Small Business Innovative Research Grant (SBIR) from The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) to develop efficacious and highly selective inhibitors of CYP26s for the topical treatment of ichthyosis for $1.5 million.
  • 2019 Phase 1 STTR grant funding from the National Institute of Neurological Disorders and Stroke to support preclinical efficacy studies for a novel drug treatment for pruritus for up to $1.5 million.

Dermaxon is partnered with ASCEND innovation award winner Stephen Lodmell and has attended many ASCEND webinars in the past. Congratulations to the Dermaxon team on these notable accomplishments! For more information please visit the Dermaxon website here: https://dermaxon.com/.

Read 100 times Last modified on Tuesday, 31 August 2021 16:06